Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase…

Overview of attention for article published in Annals of the Rheumatic Diseases, May 2012

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

policy: 1 policy source
twitter: 1 X user
patent: 5 patents

guideline: 8 clinical guideline sources
bluesky: 1 Bluesky user

Readers on

mendeley: 219 Mendeley

So far, Altmetric has seen 1 policy document that references this research output.

Belimumab Treatment for Adults with Systemic Lupus Erythematosus: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Cited by Canadian Agency for Drugs and Technologies in Health (CADTH) on 12 Oct 2018

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

This page shows the most recent policy documents that mention this research output. Click here to find out how to access more activity.